Featured
THE ASCRS INNOVATION AVALANCHE
OM’s editorial board members pick their favorite new drugs and devices from the 2023 meeting.
By RENE LUTHE
SHEDDING LIGHT ON GEOGRAPHIC ATROPHY
How to diagnose this disease and monitor progression and visual function
By Elizabeth Yeu, MD, Margaret Chang, MD, MS
GA THERAPIES ON THE WAY
A look at the treatment pipeline for geographic atrophy secondary to AMD
By Hannah Khan, MPH, Aamir A. Aziz, BS, Carl Danzig, MD, et al.
THE FUTURE OF NEOVASCULAR AMD TREATMENT
These recent and pipeline therapies could reduce the treatment burden for you and your patients.
By NARINE VIRUNI, MD, KAPIL MISHRA, MD
AI ADVANCES FOR DIABETIC RETINOPATHY
How artificial intelligence can be a useful tool for the screening and evaluation of diabetic eye disease
By KAREN MATAR, MD, YAVUZ CAKIR, MD, Justis P. Ehlers, MD
ON THE HORIZON: DIABETIC RETINOPATHY TREATMENTS — WITHOUT INJECTIONS
Emerging agents and delivery systems offer alternatives to intravitreal anti-VEGF injections.
By CAROLINE C. AWH, MD, Peter K. Kaiser, MD
GENE THERAPY FOR RETINAL DISEASES
A look at the latest updates in gene therapy for inherited and acquired retinal diseases
By YUXI ZHENG, MD, Lejla Vajzovic, MD, FASRS
Departments
BEST PRACTICES
5 WAYS TO OPTIMIZE YOUR REVENUE CYCLE MANAGEMENT
By ELIZABETH MONROE, COE, CPSS, PHR, LAURIE K. BROWN, MBA, COMT, COE, CPC, CPMA, CPSS, LSSYB
SOCIAL MEDIA HACKS
CHATGPT: AI-ASSISTED BUSINESS MANAGEMENT
By DAGNY ZHU, MD, JASMINE MAHAJAN, BS, ARETHA ZHU, BS
RX PERSPECTIVE
GEOGRAPHIC ATROPHY FINALLY GETS A THERAPEUTIC FOE
By Joseph F. Jalkiewicz, contributing writer